Compare ARK Genomic Revolution ETF (ARKG) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Oklo Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.64, while Oklo Inc trades at $46.55 (market cap $8.50B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | OKLO | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $174.14 |
52-Week Low | $23.09 | $45.58 |
Market Cap | — | $8.50B |
Enterprise Value | — | $6.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
OKLO trades at $48.85, down 0.85% on the day, reflecting ongoing volatility as the stock remains 70% below its 52-week high. Technical indicators show a bearish trend with support at $45, while fundamentals reveal significant losses with a net income of -$105.66M in 2025. Recent news highlights progress with DOE safety approvals for its Groves reactor, but investor sentiment is mixed amid substantial cash burn and equity dilution from financing activities.
The outlook hinges on successful reactor deployment and commercialization, with analyst consensus pointing to 96% upside potential. Key risks include execution delays, regulatory hurdles, and persistent negative cash flow from operations. Long-term growth depends on converting nuclear technology advancements into revenue, making it a high-risk, high-reward opportunity for speculative investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
